Login / Signup

Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.

Kazuki YanagidaTaketo KawaiToyoshi SeitoKensuke MatsumotoTomoyuki KanekoTohru Nakagawa
Published in: IJU case reports (2024)
This is the first report of the development of myelodysplastic syndrome during enfortumab vedotin therapy in a clinical setting. Although rare, myelodysplastic syndrome can occur during enfortumab vedotin therapy.
Keyphrases
  • hodgkin lymphoma
  • squamous cell carcinoma
  • stem cells
  • mesenchymal stem cells
  • cell therapy
  • replacement therapy
  • smoking cessation